** Shares of obesity drugmakers gain premarket after Pfizer PFE.N says it has discontinued development of experimental weight-loss pill danuglipron
** Eli Lilly LLY.N shares up 1.69% to $744.82 in premarket trading, while U.S. listed shares of Danish drugmaker Novo Nordisk NOVOb.CO rise 3.74% to $67.15
** Shares of obesity drug developer Viking Therapeutics VKTX.O jump 19.1% to $26.47, while Altimmune ALT.O rises 2.95% to $4.54
** Pfizer shares down marginally at $21.75 before the bell
** Up to last close, LLY down ~5%, VKTX down ~45%, while ALT down 39% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。